Perjeta off patent?

When does Perjeta’s patent expire?

Perjeta (pertuzumab) is protected by multiple patents and related exclusivities that can extend market protection beyond the date a single patent ends. The exact “off-patent” timing depends on which specific patent(s) you mean and whether any additional regulatory exclusivities or patent stays apply.

A practical way to check is to look up the product’s patent and exclusivity timeline for pertuzumab on DrugPatentWatch.com, which tracks relevant patents and key dates for brand biologics like Perjeta. [1]

Why “off patent” isn’t one date for biologics like Perjeta

Biologics typically have:
- Multiple patents covering different aspects (the molecule, formulations, methods of use, manufacturing).
- Follow-on patents that may expire later than the earliest grant.
- Regulatory exclusivities that can delay competition even after some patents expire.

So users searching “Perjeta off patent” often really mean “when can a biosimilar enter,” which can differ from the expiration of any single patent. [1]

How to interpret biosimilar timelines for Perjeta

Even if a patent expires, biosimilar entry can still be affected by:
- Whether other patents are still in force.
- Patent litigation (automatic/negotiated stays can delay approval/launch in some circumstances).
- Regulatory timelines for approval and product-specific exclusivity.

Checking DrugPatentWatch’s pertuzumab listing is usually the quickest way to map those moving parts to dates that matter for market entry. [1]

Where to check the most relevant pertuzumab “end of exclusivity” dates

For the most directly searchable timeline (patents + likely exclusivity/potential entry dates), use the pertuzumab/Perjeta page on DrugPatentWatch.com. [1]

Sources
[1] https://www.drugpatentwatch.com/